Lenalidomide Grindeks

Lenalidomide, the active ingredient in Lenalidomide Grindeks, is an immunomodulatory drug presented as an oral formulation for oral use. It is indicated for certain blood cancers, including multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma, and is prescribed for adult patients under specialist supervision.

GNH USA supplies Lenalidomide Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Lenalidomide is used in hematologic malignancies that rely on abnormal plasma‑cell or lymphoid proliferation.

Multiple myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease. Myelodysplastic syndromes with del(5q): induces transfusion independence and cytogenetic remission in eligible patients. Mantle cell lymphoma: contributes to disease control when combined with other agents in relapsed or refractory settings.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue - Constipation - Rash - Neutropenia

Serious or Rare Side Effects: - Venous thromboembolism - Severe neutropenia - Secondary primary malignancies - Teratogenic effects

Lenalidomide requires careful monitoring and specific safety measures.

Pregnancy: contraindicated due to known teratogenicity; effective contraception is mandatory. Thrombosis risk: assess individual VTE risk and consider prophylaxis when appropriate. Blood counts: perform regular complete‑blood‑count monitoring to detect myelosuppression. Renal impairment: evaluate kidney function and adjust dose as recommended. Drug interactions: review concomitant medications for potential interactions. Store below 25°C: keep in the original pack, protect from moisture.

Lenalidomide can interact with several medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (warfarin, DOACs): increased risk of thrombosis. - Strong CYP3A4 inducers (rifampin, carbamazepine): may reduce lenalidomide exposure. - Live vaccines: heightened risk of infection.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (ketoconazole, itraconazole): may increase drug exposure. - Other immunomodulatory agents (pomalidomide, thalidomide): additive myelosuppression. - Hormonal contraceptives: reduced effectiveness, require additional barrier methods. - NSAIDs: may exacerbate renal impairment, especially in patients with pre‑existing kidney disease.